Allogene Therapeutics granted three Fast Track Designations for ALLO-329
Allogene Therapeutics (ALLO) announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast ...
MPR21h
Tau-Targeting Antisense Therapy for Alzheimer Disease Gets Fast Track Status
BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.
CURE3d
FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma
The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when ...
Are Psychedelics A Way To Fast-Track Healing Trauma? We Road-Tested Ketamine
Enter psychedelics like ketamine, psilocybin, and MDMA, which are being explored as tools to access and process these buried ...
Zacks Investment Research on MSN4d
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...
PharmExec5d
FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidate
BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...
BioSpace5d
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier
After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...
Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...
The Manila Times5d
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
"We are encouraged by the FDA's Fast Track designation for BIIB080, which highlights the urgent need for innovative ...
Biogen announces U.S. FDA granted Fast Track designation to BIIB080
Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...
CURE6d
First Patient Dosed With Annamycin and Cytarabine in Phase 3 AML Trial
The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...